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Background and Aims: Neurogenic dysphagia linked to failed relaxation of the upper
esophageal sphincter (UES) can be treated by injecting botulinum toxin (BTX) into the
cricopharyngeal (CP) muscle. We compared the effects of this treatment in different
neurological disorders with dysphagia, to evaluate its efficacy over time including the
response to a second injection.
Materials and Methods: Sixty-seven patients with neurogenic dysphagia associated
with incomplete or absent opening of the UES (24 with brainstem or hemispheric
stroke, 21 with parkinsonian syndromes, 12 with multiple sclerosis, and 10 with
spastic-dystonic syndromes secondary to post-traumatic encephalopathy) were treated
with the injection of IncobotulinumtoxinA (dose 15–20 U) into the CP muscle under
electromyographic guidance. The patients were assessed at baseline and after the
first and second treatment through clinical evaluation and fiberoptic endoscopy of
swallowing, while their dysphagia was quantified using the Dysphagia Outcome and
Severity Scale (DOSS). An electrokinesiographic/electromyographic study of swallowing
was performed at baseline.
Results: Most patients responded to the first BTX treatment: 35 patients (52.2%) were
classified as high responders (DOSS score increase >2 levels), while other 19 patients
(28.4%) were low responders (DOSS score increase of ≤2 levels). The effect of the first
treatment usually lasted longer than 4 months (67%), and in some cases up to a year.
The treatment efficacy remained high also after the second injection: 31 patients (46.3%)
qualified as high responders and other 22 patients (32.8%) showed a low response. Only
in the parkinsonian syndromes group we observed a reduction in the percentage of
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high responders as compared with the first treatment. Side effects were mostly mild and
reported in non-responders following the first injection. A severe side effect, consisting of
ingestion pneumonia, was observed following the second BTX injection in two patients
who had both been non-responders to the first. Non-responders were characterized
electromyographically by higher values of the oropharyngeal interval.
Conclusion: These findings confirm the effectiveness of IncobotulinumtoxinA injection
in the treatment of neurogenic dysphagia due to hyperactivity and relaxation failure of
the UES. Caution should be used as regards, the re-injection in non-responders to the
first treatment.
Keywords: botulinum toxin, neurogenic dysphagia, electrophysiological study of swallowing, cricopharyngeal
muscle, upper esophageal sphincter dysmotility
INTRODUCTION
Neurogenic dysphagia associated with failed relaxation of
the upper esophageal sphincter (UES) has been observed
in patients suffering from different types of neurological
disease, such as parkinsonisms, multiple sclerosis (MS)
and stroke (Regan et al., 2014). The absent relaxation of
the cricopharyngeal (CP) muscle during bolus swallowing
prevents the UES from opening; consequently, the bolus
cannot progress into the esophagus. This may result
in penetration or aspiration of ingested food into the
airways.
Botulinum toxin (BTX) is one of the most effective options
for the treatment of neurological disorders characterized by
dysfunction of striated muscle (hyperactivity, dyskinesia, or
prolonged spasms) (Orsini et al., 2015; Sivaraman Nair, 2016).
Several reports in the literature indicate that neurogenic
dysphagia associated with UES spasms or dyskinesia can be
effectively treated by injecting BTX into the CP muscle (Ahsan
et al., 2000; Alberty et al., 2000; Haapaniemi et al., 2001;
Moerman, 2006; Krause et al., 2008; Terré et al., 2008, 2013;
Alfonsi et al., 2010; Restivo et al., 2013; Regan et al., 2014).
However, most of these reports are case series formed by a low
number of patients, while randomized control trials are lacking.
Moreover, because of different methodological approaches, study
designs and outcome measures, the results obtained by different
authors are not strictly comparable. Indeed patients’ selection
criteria vary greatly from study to study, and the same is
also true for follow-up times: some authors have focused only
on short-term safety and efficacy of BTX treatment, while
others have investigated long-term effects (Ahsan et al., 2000;
Haapaniemi et al., 2001; Shaw and Searl, 2001; Zaninotto
et al., 2004; Terré et al., 2008, 2013; Woisard-Bassols et al.,
2013).
Oropharyngeal swallowing, in its different phases, can
be investigated using a combined electrokinesigraphic/
electromyographic method that includes multichannel recording
of the EMG activity of the submental/suprahyoid muscle
complex and the CP muscle (the main portion of the UES),
and mechanographic recording of the kinematic aspects of the
pharyngeal-laryngeal structures occurring during the pharyngeal
phase of swallowing.
In a previous electrokinesiographic/electromyographic study
of swallowing (EES), we showed that BTX injected into the
hyperactive CP muscle of patients with dysphagia can restore
the brief disappearance of EMG activity (inhibitory pause) that
normally occurs in this muscle during the pharyngeal phase
of swallowing (Alfonsi et al., 2010). We also identified specific
alterations in the electrophysiological patterns of oropharyngeal
swallowing, some of which are frequently associated with
inefficacy of BTX treatment. A recent Cochrane review on the
use of BTX in neurogenic dysphagia concluded that there is still
insufficient evidence to inform clinical practice (Regan et al.,
2014). Indeed, although it has been suggested that there may be
different reasons for failure of BTX injection into the CP muscle
to treat neurogenic dysphagia (Alfonsi et al., 2010), the factors
that may influence the therapeutic response or predict the risk of
side effects, thus contraindicating the treatment, are still poorly
understood (Regan et al., 2014). In addition, there are currently
no studies comparing the effectiveness of this BTX treatment in
different neurological disorders with dysphagia associated with
failed UES relaxation.
Therefore, the main aims of this study were: (1) to analyze
the safety and effectiveness of BTX treatment for neurogenic
dysphagia in different neurological diseases characterized by
abnormally reduced or absent relaxation of the CP muscle, (2)
to evaluate consistency of effectiveness over two subsequent
injections, and 3) to search for reliable EES indicators of
responsiveness to the BTX treatment.
MATERIALS AND METHODS
Ethics Statement
The study protocol was approved by the Ethics Committee of the
C. Mondino National Neurological Institute. All the patients gave
their informed consent to all the study procedures.
Subjects
In this prospective, observational study, we enrolled 67 patients
consecutively hospitalized at our institute suffering from
neurogenic dysphagia associated with incomplete or absent
opening of the UES due to hypertonia and/or dyskinesia of the
CP muscle. The main characteristics of the patients – 41 men and
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26 women (mean age ± SD: 63.5 ± 13.5 years; age range: 43–
87 years) – are summarized in Table 1. Twenty-four of them had
suffered a stroke more than six months previously: the lesion was
located in the lateral medullary region (Wallenberg syndrome)
in 14 subjects, while the remaining 10 had a lesion in one
hemisphere. Twenty-one subjects had parkinsonian syndromes;
of these, 12 had idiopathic Parkinson’s disease (PD) diagnosed
according to the U.K. Parkinson’s Disease Brain Bank criteria
(Hughes et al., 1992), and were examined during the “on”
phase of the levodopa response cycle, five had multiple system
atrophy, parkinsonian variant (MSA-P), diagnosed according to
the criteria of the ‘2nd Consensus Statement on the diagnosis
of multiple system atrophy’ (Gilman et al., 2008), and four had
progressive supranuclear palsy (PSP) diagnosed as per the criteria
proposed by NINDS-SPSP (Litvan et al., 1996). Twelve patients
had MS: nine with the secondary progressive form, and three with
the primary progressive form diagnosed according to McDonald
et al. (2001). The remaining 10 patients had stabilized symptoms
of spastic dystonia due to post-traumatic encephalopathy.
Methods
All the patients underwent bedside examination (BSE) and
fiberoptic endoscopic evaluation of swallowing (FEES). Based on
findings from BSE and FEES, dysphagia was graded according
to the Dysphagia Outcome and Severity Scale (DOSS) (O’Neil
et al., 1999), which allowed the identification of the following
three levels of dysphagia: scores 5 and 4=mild dysphagia; scores
3 and 2=moderate dysphagia; score 1= severe dysphagia.
Fiberoptic endoscopic evaluation of swallowing provides
static and dynamic evaluation of the structures involved in
the swallowing act. For the evaluation of these aspects, FEES
compares well with videofluoroscopy (VFS) (Horner et al.,
1993; Doggett et al., 2001). However impaired opening of
UES may be only indirectly inferred with FEES when residual
material is viewed in the pharyngeal recesses immediately
after the “white out” phase, during which larynx adducts,
pharynx constricts and epiglottis falls over the opening to
the upper airway (Hiss and Postma, 2003). For this reason,
FEES cannot be used to establish whether poor or absent UES
opening is due to impaired relaxation of the CP muscle or
to a mechanical dysfunction leading to impaired elevation and
anterior movement of the laryngeal-pharyngeal structures during
swallowing (Lang and Shaker, 2000; Sivarao and Goyal, 2000).
Therefore, we also performed an EES to identify patients in
whom incomplete or absent opening of the UES was due to a
relaxation deficit of the CP muscle. EES was performed according
to the methods of Ertekin et al. (1995) and Alfonsi et al.
(2007), and it involved simultaneous, three-channel recording
(Figure 1). The first channel recorded the EMG activity of the
suprahyoid/submental muscles using surface electrodes. This
activity marks the beginning of the propulsive action of the
suprahyoid/submental muscles in the oral and pharyngeal phases
of swallowing. The second channel recorded the EMG activity of
the CP muscle using a concentric needle inserted through the
skin at the level of the cricoid cartilage, about 1.5 cm posterior
to its palpable lateral border, in the posteromedial direction.
The CP muscle is a major contributor to the functional area TA
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FIGURE 1 | Electrokinesiographic/Elecromyographic study of swallowing (EES). In each panel the upper trace represents the surface EMG activity of the
suprahyoid/submental muscle complex, the middle trace the needle-EMG activity of the cricopharyngeal muscle (CP), and the lower trace is the mechanogram
obtained from a piezoelectric transducer applied to the skin over the cricothyroid membrane. In (A,B): traces recorded from a normal subject. The EMG pause of the
CP muscle is evident on both sides (A: left; B: right). In (C,D): patient with stroke lesion of the left hemisphere and paresis on the right side. The EMG pause of the
CP muscle is bilaterally reduced, more in the right side (D) as compared to the left one (C). Botulinum toxin (BTX) was injected into the right side of the CP muscle. In
(E,F): patient with spastic-dystonic syndrome in post-traumatic encephalopathy. EMG pause of the CP muscle is absent on both sides. Asymmetric tonic EMG
activity of the CP muscle can be observed, being the EMG amplitude in the right side (F) greater than in the left one (E). BTX was injected into the right side of the
CP muscle. Arrows indicate pause of the EMG activity of the CP muscle.
known as the UES and at rest it shows tonic EMG activity
related to its function as a sphincter (Lang and Shaker, 2000);
during the pharyngeal phase of swallowing this EMG activity
disappears completely for a brief time (inhibitory pause). During
this pause, the amplitude of the EMG signal from this muscle
falls below 50 µV (Alfonsi et al., 2010). The duration of the
EMG pause of the CP muscle (CPEMG-PD) depends on the
consistency and volume of the bolus (Lang and Shaker, 2000;
Sivarao and Goyal, 2000) and ranges from 150 to 700 ms
(mean ± SD: 470 ± 160 ms) according to the reference values
obtained in our laboratory in a population of 40 healthy subjects
(25M/15F, mean age ± SD: 58.3 ± 15.1 years; age range: 45–
80 years) (Alfonsi et al., 2007, 2013). EMG signals from the
first and second channels were rectified and bandpass filtered
between 100 and 2 KHz. The third channel recorded the signal
obtained from a piezoelectric transducer applied to the skin
over the cricothyroid membrane. This transducer consists in a
rectangular strip with a triangular rubber button in the center,
which was applied to the skin over the cricothyroid membrane
and kept in place by adhesive tape wrapped around the neck.
It showed a linear force-to-signal ratio for forces ranging from
0.1 to 300 g. Its signals were bandpass filtered between 0.01 and
30 Hz. This device is able to record the moment of epiglottis
elevation/retroflection and also the moment of its return to the
rest position.
For EES, each subject was examined while seated with the
head held in a natural position; a small volume of water (3 ml)
was infused directly into the oral cavity using a disposable
syringe. This was done gradually (over a period of 2 s) in order
to avoid squirting the water into the posterior pharynx. The
subject was instructed to keep the bolus at mid-tongue level,
and thereafter, on feeling the liquid to be in the right position,
to swallow it. We deliberately used a small fluid bolus (3 ml)
to test swallowing activity because swallowing such a bolus
requires a greater level of neural activation in individuals with
neurological disorders (Kaas et al., 1983). In addition, given the
risk of aspiration in dysphagic patients, this approach constituted
a safety measure.
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In addition to the above, two other electrophysiological
parameters were evaluated in each patient: (1) the
interval between the onset of the EMG activity of the
submental/suprahyoid muscle (SHEMG) complex and the
onset of the laryngopharyngeal mechanogram (LPM) measured
in ms (I-SHEMG-LMP) (normal mean values± SD: 200± 84 ms,
range: 55–370 ms, obtained as for CPEMG-PD); (2) the duration
of the SHEMG (SHEMG-D) measured in ms (normal mean
values± SD: 1126± 264 ms, range: 700–1820 ms, obtained as for
CPEMG-PD). We decided to evaluate these parameters because
I-SHEMG-LMP values greater than 300 ms, and SHEMG-D
values greater than 1680 ms or below 1000 ms, recorded in a 3 cc
liquid bolus swallowing task, were previously found to negatively
influence the response to the BTX treatment in patients with CP
muscle hyperactivity (Alfonsi et al., 2010).
Failure of relaxation was defined as complete when the
EMG pause of the CP muscle (EMG-CP-pause) was absent,
i.e., the EMG signal never fell below 50 µV (Alfonsi et al.,
2010) or when the EMG signal fell below the lower limit of
the normal CPEMG-PD range (less than 150 ms). Patients were
considered eligible for BTX injection only if EES confirmed
the failure of CP relaxation during the pharyngeal phase of
swallowing.
The injection procedure was carried out using a needle
electrode cannula (monopolar electrode), while monitoring the
EMG activity of the muscle. This electrode was inserted in
the neck at the level of the cricoid cartilage in the manner
described above; a surface electrode (reference electrode) was
applied ipsilaterally over the midline of the clavicle. The BTX
injection was performed unilaterally in all patients because
bilateral injection could have increased the risk of aspiration.
Indeed, BTX not only favors CP muscle relaxation during
the pharyngeal phase of swallowing, but it can also reduce
the tonic muscle contraction, as shown in studies using
esophageal manometry (Terré et al., 2008). Thus, loss of the
sphincter activity of the CP muscle would increase the risk
of food reflux from the esophagus, and consequent post-
deglutition aspiration into the airways (Shaker and Hogan,
2000). A further reason for choosing unilateral injection was
to reduce the effects of potential contamination of nearby
muscles involved in vocal cord movement (the posterior and
lateral cricoarytenoideus muscles) and pharyngeal peristalsis (the
inferior constrictor muscle). Patients with unilateral spasticity,
such as stroke patients, most of the patients with spastic-
dystonic encephalopathy, and some of the patients with MS
were injected with BTX on the paretic side, as the CP
muscle tonic activity and impaired relaxation during swallowing
were always greater on this side than contralaterally. In the
other patients, the BTX injection was performed on the side
showing greater CP muscle hyperactivity (i.e., greater mean
amplitude of the tonic EMG activity at rest in a time of 5 s)
(Figure 1).
In each patient, a 15 or 20 U dose of BTX
(IncobotulinumtoxinA- Xeomin R©; Merz, Frankfurt, Germany),
diluted 5.0U/0.1 ml, was injected into the CP muscle on one
side. The 15 U dose was used in patients in whom the baseline
amplitude of the EMG signal from the CP muscle fell below
20 µV during the pharyngeal phase of swallowing, and the
20 U dose in those in whom it failed to drop below this
level.
Design of the Study
The study was conducted as a prospective observational
investigation in which all patients with absent opening of the
UES documented by FEES and an absent or incomplete EMG-
CP-pause during the pharyngeal phase of swallowing underwent
BTX injection into the CP muscle.
One month after BTX injection the patients were re-
evaluated with BSE and FEES and arbitrarily classified as high
responders, when the DOSS score increased by >2 levels (e.g.,
marked improvement of dysphagia from severe to mild), low
responders when the DOSS score had increased by≤2 levels (e.g.,
improvement of dysphagia from severe to moderate, or from
moderate to mild), and non-responders when no score change
was detected or DOSS score indicated a worsening of dysphagia.
In each patient, the duration of the therapeutic effect of the first
BTX injection was monitored by means of monthly clinical and
FEES evaluations. For statistical purposes, the duration of BTX
effect was stratified as follows: <2 months, 2–4 months, and
>4 months. In responders, a second BTX injection was given
when the DOSS score had returned to its baseline value. In non-
responders a second BTX injection was administered one month
after the first one.
Adverse events were carefully recorded at each clinical
evaluation and were defined as mild when they did not
interfere with normal daily living, moderate when they required
medical treatment, and severe when hospitalization was required
and/or life-threatening manifestations occurred. Regardless of
the scheduled follow-up, all patients were advised to call or return
to our Center if unexpected side effects occurred.
The primary outcome measure was the DOSS score change
one month after injection, whereas the secondary outcome
measure was the duration of the therapeutic effect of the first BTX
injection.
Statistical Analyses
Statistical analyses were performed using the Statistical Package
for Social Sciences (SPSS) version 21.0 for Windows. Categorical
variables were plotted in cross-tables and analyzed by means of
the chi-square test. For the analysis of continuous variables, we
first evaluated whether or not they showed a normal distribution,
using a test for normality (Kolmogorov–Smirnov): SHEMG-D
proved to be normally distributed, therefore differences between
groups were tested with a parametric ANOVA, followed by a
post hoc Bonferroni’s test; I-SHEMG-LMP was not normally
distributed and so statistical analysis was performed by running
a Kruskal–Wallis test followed by a Mann–Whitney test with
Bonferroni’s correction. For each electrophysiological parameter,
we considered the occurrence of values exceeding the normal
limits, the normal range being taken to correspond to the 5th–
95th percentile computed in a control group (reference values of
our laboratory). The level of significance was set at 0.05 for each
test.
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RESULTS
Table 1 describes the epidemiologic and clinical features of the
study population at baseline. Seventeen of the 67 enrolled patients
had severe dysphagia (7 with lateral medullary stroke, 6 with
parkinsonian syndrome, 2 with post-traumatic encephalopathy,
and 2 with MS), 30 had moderate dysphagia (7 with bulbar
ischemia and 4 with unilateral hemispheric stroke, 7 with
parkinsonian syndrome, 8 with post-traumatic encephalopathy,
and 4 with MS), and the remaining 20 had mild dysphagia (6 with
unilateral hemispheric stroke, 8 with parkinsonian syndrome,
and 6 with MS). The clinical response to the first and second BTX
injections into the CP muscle in this population is described in
Table 2.
Safety of the Treatment
After the first BTX inoculation, some drug-related mild side
effects were observed in 10 of the 13 patients classified
as non-responders (15% of total number of patients). In
particular, in seven patients we observed a transient worsening
of dysphagia for a period ranging from 1 week (in 2 patients
with brainstem stroke) to 3 weeks (in 2 patients with PD,
1 patient with PSP, 1 with MSA-P, and 1 with previous
lateral medullary stroke). In the other three patients, we
observed transitory dysphonia (breathiness/whispering voice)
lasting 1 week in one case (a patient with previous stroke
in one hemisphere) and 2 weeks in the other two cases (1
patient with PD and 1 with PSP). In all cases the adverse
effects did not require any dietary changes, medical treatment or
hospitalization.
As regards, the second BTX injection, two of the non-
responders (1 with MSA-P and 1 with PSP) showed, about one
month after the treatment, a severe side effect consisting of
ingestion pneumonia, which was associated with a worsening
of their dysphagia. Both patients were hospitalized, treated with
antibiotics, and recovered in a period of about 10 days. The side
effect was considered possibly related to the drug, although, as
both subjects were non-responders, we cannot exclude that it
was simply related to the persistence/worsening of the underlying
disease.
In addition, between one and three days after second injection,
five patients (3 with PD, 1 with MSA-P, and 1 with previous bulbar
stroke), all of whom non-responders, showed mild dysphonia
(breathiness/whispering voice) lasting 1 week and not requiring
any treatment.
Effectiveness of the Treatment
The main results are summarized in Table 2. Fifty-four of the 67
patients examined (81%) showed a clinical response after the first
treatment with BTX: 35 patients (52.2%) were classified as high
responders while other 19 patients (28.4%) were low responders
based on the DOSS score changes observed at the first 1-month
follow-up (Figures 1 and 2). The remaining 13 patients (19.4%)
were non-responders: 10 patients showed no change in the DOSS
score, and 3 patients showed a reduction of the baseline DOSS
score.
The beneficial clinical effect of the first treatment lasted more
than 4 months (range: 18 to 46 weeks) in 36 of the 54 responders
(67%), between 2 and 4 months (range: 8–16 weeks) in 16 (30%)
and less than 2 months (range: 6–7 weeks) in the remaining
two (4%) (see Table 3 for more details). The chi-square test
showed that the duration of the beneficial effects of the BTX
treatment differed between diseases, being longer in patients
with post-traumatic encephalopathy and shorter in parkinsonian
syndromes (χ2 = 8.22, df = 3, p= 0.043).
With regard to the electrophysiological assessment, five of the
13 patients classified as non-responders (38.5%) had SHEMG-D
values that fell below the normal range, in one case associated
with an increase in the I-SHEMG-LMP; three patients (23.1%)
showed increased SHEMG-D and I-SHEMG-LMP values; two
(15.4%) showed an abnormal increase only in the I-SHEMG-
LMP parameter. Three of the 13 non-responders (23.1%) showed
normal values both for SHEMG-D and for I-SHEMG-LMP.
The SHEMG-D value was above the normal limit in four of the
36 high responders (11.1%) and three of the 18 low responders
(16.7%), while the I-SHEMG-LMP value was above the normal
TABLE 2 | Efficacy of BTX treatment in neurogenic dysphagia (1 month after BTX injection).
Total Parkinsonian syndromes Stroke Post-traumatic
encephalopathy
Multiple
Sclerosis
PD MSA-P PSP Cerebral lesion Brainstem lesion
Number of cases 67(%) 12 5 4 10 14 10 12
First injection of BTX
High responder 35 (52%) 6 (50.0%) 2 (40.0%) 1 (25.0%) 7 (70.0%) 4 (28.6%) 8 (80.0%) 7 (58.3%)
Low responder 19 (28%) 4 (33.3%) 2 (40.0%) 1 (25.0%) 1 (10.0%) 7 (50.0%) 2 (20.0%) 2 (16.7%)
Non-responder 13 (19%) 2 (16.7%) 1 (20.0%) 2 (50.0%) 2 (20.0%) 3 (21.4%) 0 (0.0%) 3 (25.0%)
Second injection of BTX
High responder 31 (46.3%) 2 (16.7%) 0 (0.0%) 0 (0.0%) 4 (40.0%) 3 (21.4%) 10 (100%) 3 (25.0%)
Low responder 22 (32.8%) 7 (58.3%) 4 (80.0%) 2 (50.0%) 5 (50.0%) 8 (57.2%) 0 (0.0%) 5 (41.7%)
Non-responder 14 (20.9%) 3 (25.0%) 1 (20.0%) 2 (50.0%) 1 (10.0%) 3 (21.4%) 0 (0.0%) 4 (33.3%)
First vs. second injection: χ2 = 16.16, df = 4, p = 0.003. PD, idiopathic Parkinson’s disease; MSA-P, multiple system atrophy, parkinsonian variant; PSP, progressive
supranuclear palsy.
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FIGURE 2 | High responders, low responders, and no-responders treated with injection of BTX into the CP muscle. Values (median and interquartile
range) of the electrophysiological parameters. (A) Duration of the EMG activity of suprahyoid /submental muscle complex (SHEMG-D), and (B) interval between the
onset of the EMG activity of the submental/suprahyoid muscle complex and the onset of the laryngopharyngeal mechanogram (I-SHEMG-LMP).
limit in only five of the high responders (13.9%) and two of the
low-responders (11.1%).
The I-SHEMG-LMP parameter was statistically higher in the
non-responders compared with the high responders (Z = –2.49,
p = 0.01). Indeed, no significant differences were observed
between high responders and low responders or between low
responders and non-responders (Figure 2B). The SHEMG-
D parameter did not show significant differences between
high responders, low responders and non-responders to BTX
treatment (Figure 2A). This was probably due to the high
variability of this parameter in the group of non-responders,
in which both abnormally increased and decreased values were
observed.
All the patients received the second BTX treatment as we did
not observe any severe side effects after the first BTX injection.
Fifty-three of the 67 patients examined (79%) were responsive
to the second treatment with BTX: 31 patients (46.3%) showed
a high response, 22 patients (32.8%) a low response, and the
remaining 14 patients (20.9 %) were non-responsive to the
treatment (see Table 2 for more details).
The chi-square test revealed a significant difference in the
distribution of high/low responders and non-responders between
the first and the second BTX treatment with a reduction in
the efficacy of the treatment following the second injection
(χ2 = 16.16, df = 4, p= 0.003). This was mainly due to a reduction
of efficacy in the group of patients with parkinsonian syndromes
in which the percentage of high responders fell from 42.8% (9 out
of 21 patients) to 9.5 % (2 out of 21 patients).
DISCUSSION
The results of our study confirm the efficacy of BTX injection
for the treatment of neurogenic dysphagia associated with
hyperactivity of the CP muscle. As shown by the DOSS score
changes after the first BTX treatment, dysphagia improved in
more than 80% of patients with beneficial effects that lasted over
4 months in most of them. In agreement with previous findings
of other groups, in some cases the efficacy of the treatment lasted
up to one year (Ahsan et al., 2000; Haapaniemi et al., 2001; Shaw
and Searl, 2001; Zaninotto et al., 2004; Terré et al., 2008, 2013;
Woisard-Bassols et al., 2013). Overall, our results are in line with
the findings reported in a review of the literature, showing that
the mean success rate of BTX in the management of dysphagia
linked to dysfunction of the CP muscle is of 76%, similar to that of
myotomy (75%) (Kocdor et al., 2016). However, it is noteworthy
that the success rates reported in the different studies may vary
between 43 and 100%. This is likely due to different variables
TABLE 3 | Duration of the effects of first BTX injection in responders with neurogenic dysphagia.
Total Parkinsonian syndrome Stroke Post-traumatic encephalopathy Multiple Sclerosis
Number of cases 54 16 19 10 9
<2months 2 (3.7%) 2 (12.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
2–4 months 16 (29.6%) 6 (37.5%) 4 (21.1%) 1 (10.0%) 5 (55.6%)
>4 months 36 (66.7%) 8 (50.0%) 15 (78.9%) 9 (90.0%) 4 (44.4%)
Differences between neurological disorders: χ2 = 8.22, df = 3, p = 0.043.
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including patients’ selection, technical aspects (e.g., injection of
BTX under endoscopy or EMG guidance), and injection sites and
total dose of BTX. For instance, some authors have used a higher
BTX dose (100 U) than that used in the present study, and they
have injected it in three different sites of the CP muscle under
the guidance of a flexible endoscope (Terré et al., 2008, 2013),
showing a longer lasting effect (at least 12 months) in the absence
of complications.
In the present work, we also showed that a second BTX
injection may result in an improvement of dysphagia in a large
proportion of the patients, although the improvement was less
marked, especially in the patients with parkinsonian syndromes.
The CP muscle is the main portion of the UES and its activity
as a sphincter is fundamental for controlling orthograde and
retrograde esophageal flows (Lang and Shaker, 2000; Sivarao
and Goyal, 2000). It is important to note that incomplete
or absent relaxation of the UES during swallowing does not
equate with incomplete or absent opening of this structure.
UES opening is the result of a complex interaction between
neural control and biomechanical events related to adjacent
structures, and consequently its impairment may depend on
several factors (Lang and Shaker, 2000). For instance, fibrosis
of intrinsic sphincter muscles and persistent muscle tone may
result in either diminished or absent UES opening. Furthermore,
poor pharyngeal constrictor muscle function can also result
in inefficient propulsion of the bolus from the pharynx to
the esophagus. These abnormalities, combined with absent or
incomplete opening of the UES during swallowing, can lead to
obstruction of bolus transit from the pharynx to the esophagus
and increase the likelihood of a post-deglutition aspiration of
food (Lang and Shaker, 2000; Sivarao and Goyal, 2000).
Although opening and closure of the UES during swallowing
can be indirectly documented by means of FEES (Horner
et al., 1993; Doggett et al., 2001), needle EMG is able to
directly evaluate changes in the activity of the UES muscle, thus
providing fundamental information on the pathophysiological
mechanisms underlying dysphagia (Alfonsi et al., 2010).
Therefore, conventional swallowing investigations should always
be supplemented by an EMG study for guiding the decision to
inject or not BTX into the CP muscle in patients with dysphagia.
We have previously reported that electrophysiological
investigations can reveal restoration of the normal EMG-
CP-pause after the BTX treatment (Alfonsi et al., 2010). In
this study, we confirm our previous finding that abnormal
I-SHEMG-LMP and/or SHEMG-D values can predict a negative
response to this BTX treatment (Alfonsi et al., 2010). However,
in the present study, we also found that a small proportion
of patients with abnormal I-SHEMG-LPM and/or SHEMG-D
values responded positively to the treatment. Although this
indicates that electrophysiological findings can help in selecting
which patients to treat, ultimately the decision in an individual
patient should not be taken only on the basis of the presence or
absence of electrophysiological abnormalities. Indeed, in some
cases, suprahyoid/submental muscle dysfunction may be a less
important factor in inducing dysphagia than abnormal UES
opening. For instance, in patients with camptocormic postures
and neck flexion, the synergistic action of other muscles,
such as the infrahyoid muscles, could compensate for the
bradykinesia/hypokinesia of the suprahyoid/submental muscle
complex (Lang and Shaker, 2000) that may be responsible for
increased SHEMG-D values.
As regards, safety of the BTX treatment, our findings are in line
with the complication rates reported in the literature, which range
from 0 to 25% (Kocdor et al., 2016). Indeed, in 15% of our patients
(all non-responders), the first BTX injection into the CP muscle
was associated with mild side effects, namely transient worsening
of the dysphagia or the appearance of dysphonia (whispering
and breathiness). These side effects were likely related to the
inadvertent diffusion of BTX to nearby muscles. Diffusion of BTX
from the injection site to muscles situated above it, such as the
inferior constrictor muscle of the pharynx, may indeed result
in impaired pharyngeal peristalsis, while its diffusion to nearby
tensor and abductor muscles of the vocal cords may result in voice
and breathing abnormalities. These side effects might be limited
by reducing the BTX dilution (Alfonsi et al., 2010). Conversely,
it is possible that in the non-responders who did not manifest
side-effects might have benefitted from higher doses of the toxin.
Though after the second BTX injection we recorded a lower
rate of adverse events (10%), a severe side effect was observed
in two patients (3%) who were both non-responders to the first
BTX injection and had undergone the second treatment after
1 month. This suggests caution in the repetition of treatment in
non-responders. The choice to repeat the treatment should be
carefully weighed against the risks, possibly considering a longer
time interval from the first administration.
Our finding that side effects and complications of the BTX
injection occurred only in non-responders both after the first
and the second treatment deserves to be discussed. It may
be that, in some cases, the UES hypertonia was essentially a
protective mechanism, serving to prevent reflux of material from
the esophagus into the pharynx (Shaker and Hogan, 2000). This
mechanism might be observed in patients with gastroesophageal
reflux, however, this specific aspect was not investigated in the
present study.
In our dysphagic patients with post-traumatic
encephalopathy, the effect of the BTX treatment was more
marked after the first injection, but they also showed an
excellent response to the second treatment. Since all these
patients had a marked spastic-dystonic syndrome, it is
possible that muscle hyperactivity involving not only the
UES but also other neighboring muscles was the major
pathophysiological mechanism underlying the dysphagia in this
group. It follows that in these patients BTX injection could result
in a clinical improvement even were the toxin to diffuse to the
pharyngeal-laryngeal muscles contiguous to the CP muscle.
On the contrary, in the patients with parkinsonian syndromes
the effect of the treatment tended to decrease over time and to be
less effective when repeated. There may be different reasons for
this. First, in degenerative disorders, declining BTX efficacy could
be due to the progressive degeneration of different structures of
the central nervous system involved in the swallowing function
(Bass and Morrel, 1992; Henderson et al., 2000; Benarroch et al.,
2002; Pfeiffer, 2003). Furthermore, the lower efficacy of both the
first and second treatments in parkinsonian syndromes may also
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be due to the impaired cortical plasticity that is a consequence
of the dopaminergic deficit characteristic of these syndromes
(Eggers et al., 2010; Conte et al., 2012; Udupa and Chen, 2013); as
a result of this impaired plasticity, the capacity for modification
of swallowing behavior after BTX treatment would be reduced.
It is also noteworthy that cortical plasticity worsens during the
course of the disease (Udupa and Chen, 2013) and, in this regard,
it may be relevant that our patients presented with a relatively
long duration of the disease.
The absence of a control group is a critical limitation of this
study; however, our finding of marked clinical improvements
over a prolonged period in the majority of the patients indicates
that biases due to random fluctuations or placebo effects are
unlikely. Furthermore, given that the efficacy of BTX for the
treatment of neurogenic dysphagia is well documented (Alberty
et al., 2000; Ahsan et al., 2000; Restivo et al., 2002, 2013;
Moerman, 2006; Alfonsi et al., 2010), the use of a no-treatment
control group would pose considerable ethical problems.
CONCLUSION
The results of this study confirm previous observations that
BTX treatment is highly effective in the treatment of neurogenic
dysphagia due to hyperactivity and relaxation failure of the
UES. EES may provide useful information regarding the different
pathophysiological mechanisms at work in different kinds of
neurogenic dysphagia, thus improving the selection of patients
more likely to benefit from the BTX treatment and less likely
to experience its potential adverse effects. Finally, in our view,
an important “caveat” of BTX treatment is that absence of a
therapeutic response to the first injection should be considered
a risk factor for side possible effects (for which patients should be
closely and carefully followed up); on this basis, it should also be
taken as an indication not to repeat the treatment.
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